However, since CD38 antibody exposure is now standard of care for both transplant-eligible and ineligible populations in 2026 ...

There are now two very powerful but very different approaches that can be considered as early as first relapse for patients ...

An update on CAR-T therapies for MM and B-cell NHL presented at the 2026 ONA Summit highlighted the integral role of oncology nurses in ensuring patients achieve optimal outcomes.

CAR T-cell therapy is a one-time intensive treatment that could potentially lead to a long remission, where Tec-Dara is an ...

Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual ...

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies.

Evolution of CAR technology: from conventional CAR-T cells to diverse cellular platforms and clinical applications. An ...

FDA fully approves brexu-cel CAR‑T for relapsed mantle cell lymphoma, with ZUMA‑2 showing deep responses and key infection-care tips for clinicians. The treatment landscape for mantle cell lymphoma ...

So far, Tecvayli has had an incremental contribution to 2025 sales of $670M; while Darzalex Faspro saw $14.4B in 2025 sales.

Stakeholders responding to recent draft guidance from the US Food and Drug Administration (FDA) on the use of minimal ...

The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

CAR-T cell therapy represents an innovative form of immunotherapy, wherein T cells are genetically modified to recognize and ...